Agencies-Gaza post
U.S. approves new therapy for breast cancer
The FDA last Friday approved a new drug to treat breast cancer.
Questions were asked to Chicago hematologists and oncologists, including Dr. Basil Alatasi, an American Board of Internal Diseases, in addition to specializes in both blood and tumors.
The name of the new property is “Pham Traztezimab Dirokistan NXKI” (fam-trastuzumab-deruxtecan-nxki), also known as “Enhertu”.
Dr. Al-Atasi emphasizes that “this is a very important event that will increase the size of the category of patients benefiting from these drugs who suffer from prevalent breast cancer, and will open the way for new studies authorizing the use of these drugs in the early stages of the disease.”
What is Enhertu?
Dr. Alatasi said Enhertu is a chemotherapy treatment administered every 3 weeks to breast cancer patients and is a class of chemical drugs directed against HER2 mutations or receptors found on cancer cells.
How to give Enherto?
This property is given via IV.
To whom is Enherto given?
The drug Enherto is given to breast cancer patients of type “Her 2” (“non-removable”) or “metastatic”.
What is breast cancer Type Her 2?
According to Mayo Clinic, “protein-positive breast cancer” is breast cancer that gives a positive result to a protein called “receptor of skin growth factor 2 in humans”, and “Her 2” is an abbreviation for this name.
This protein stimulates the growth of cancer cells. Breast cancers are usually more aggressive than other breast cancers, and treatments specifically targeting Her-2 are so effective that they promise a very good destination for the disease.
What breast cancers have been approved for Enherto’s treatment?
Atasi adds that these drugs are usually administered to patients with prevalent breast cancer (Phase IV), and are among the many chemical drugs that have been proven effective in this disease.
Prior to this study, the use of this drug was restricted only to those with high HER2 receptors in Immune Colors.
